Nu-Med Plus, Inc. filed a Form 8-K on October 20, 2026, reporting that on October 19, 2026, it entered into Subscription Agreements with two accredited investors and separately issued shares to a consultant, both involving unregistered Series A Preferred Stock.
Key Highlights
- Aggregate proceeds: Two accredited investors purchased 171,232 shares of Series A Preferred Stock for a total of $450,000, or $2.628 per share, according to the filing.
- Consultant issuance: The company also issued 50,000 shares of Series A Preferred Stock to an individual consultant in consideration for services rendered.
- Conversion potential (investors): If the 171,232 investor shares were converted in full, a total of 3,424,640 shares of common stock would be issuable upon conversion.
- Conversion potential (consultant): If the 50,000 consultant shares were converted in full, a total of 1,000,000 shares of common stock would be issuable upon conversion.
- Registration exemption claimed: The company claimed an exemption from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act.
- Piggy-back registration rights: Investors were granted rights to have common stock issuable upon conversion included in any resale registration statement the company may file within two years of the subscription date.
Nu-Med Plus Series A Preferred Stock Private Placement Details
According to the filing, Nu-Med Plus, Inc. entered into Subscription Agreements on October 19, 2026, with two accredited investors under which those investors collectively purchased 171,232 shares of Series A Preferred Stock. The aggregate purchase price was $450,000, equal to $2.628 per share. The filing notes that the Subscription Agreements included "customary representations and warranties of the Investors and the Company."
Alongside the investor transaction, the company disclosed that it issued 50,000 shares of Series A Preferred Stock to an individual consultant as consideration for services rendered. The filing states that the company claimed an exemption from registration for both the investor sales and the consultant issuance under Section 4(a)(2) and/or Rule 506 of Regulation D, noting that "the offer and sale of such shares did not involve a public offering" and that recipients were each an "accredited investor." The filing also states that no sales commissions were paid in connection with the sales of these securities.
The filing specifies that the conversion ratio applicable to the Series A Preferred Stock "is not adjusted in the event of any future reverse stock split of the Company." Investors received piggy-back registration rights allowing them to have shares of common stock issuable upon conversion included in any resale registration statement relating to a secondary offering that the company may file in the two years following the subscription date, subject to certain customary requirements. The full terms are governed by the form of Subscription Agreement attached as Exhibit 10.1 to the filing.
What Was Disclosed
Nu-Med Plus disclosed an October 19, 2026, private placement of 171,232 shares of Series A Preferred Stock to two accredited investors for $450,000, plus a separate issuance of 50,000 shares to a consultant for services, both conducted under claimed exemptions from Securities Act registration.




Please wait processing your request...